Company intelligence / Profile preview

Shanghai Genomics

Shanghai, Shanghai, Chinagnimission.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company’s lead candidate F‑573 targets the caspase family for acute-on-chronic liver failure and has reached Phase 2. Other programs are in preclinical or pending stages targeting hepatitis B and chronic obstructive pulmonary disease. The company has a track record of successful collaborations with international partners such as Centocor and Inceptua

Therapeutic areas: GastroenterologyPulmonologyInfectious Diseases
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

F200

Preclinical

Partnerships

Centocor (now part of Johnson & Johnson)Inceptua GmbH

Beyond the preview

Go deeper on Shanghai Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Genomics.

Explore the full profile